Kaitlin Kraus
Primary Care · Denver, CONPI 1194333195
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 702 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 702 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$2K
- UCB, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$636
- Lilly USA, LLC$610
- Eisai Inc.$568
- plus $8K from 45 others
What the payments were for
- Food & beverage$15,66499%
- Education$2251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,889 in reported general payments places this provider in the 95th percentile of 112 primary care providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 32 | $301,997 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $90,484 |
| Emgality PenGalcanezumab-Gnlm | 48 | $63,214 |
| UbrelvyUbrogepant | 30 | $45,011 |
| EpidiolexCannabidiol (Cbd) | 19 | $32,321 |
| Nurtec OdtRimegepant Sulfate | 26 | $30,697 |
| QuliptaAtogepant | 16 | $25,840 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $18,226 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $9,427 |
| Levetiracetam | 92 | $4,076 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $3,354 |
| Lacosamide | 35 | $2,870 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 22 | $1,964 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $1,235 |
| Gabapentin | 44 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $31 | $90,48425 claims |
| AbbVieUbrelvy, Qulipta | $3,161 | $70,85246 claims |
| PfizerNurtec Odt | $1,572 | $30,69726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 primary care providers in Colorado.
Other primary care in Denver
- Mary CarrascoDenver$2K
- Jacki DegolyerDenver$2K
- Loraine van SlykeDenver$1K
- Teresa SalazarDenver$1K
- Katelyn RodgersDenver$1K
- Melanie SpottsDenver$857
- Laura VillasenorDenver$802
- Lisa LumleyDenver$593
- Danielle HamstraDenver$359
- Belinda HigaDenver$299
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.